Breaking News
TriMetis Life Sciences and Visiopharm have joined forces to offer cloud-based tissue quality control solutions. This collaboration will bring unprecedented access to AI-driven quality applications for laboratory workflow automation.
As a tissue technology company focused on accelerating research and changing healthcare, we’ve developed automated quality control applications using Visiopharm’s AI-driven precision pathology software, Oncotopix® Discovery. These applications are now part of our newly launched TriMetis ARCH Digital Ecosystem, designed for researchers, diagnostic and therapeutic developers, pathology and molecular profiling laboratories, and biobanks. If you need better information on the content of tumor tissues, ARCH can help you.
With Visiopharm’s Oncotopix® Discovery software, we can produce high-quality and high-utility applications that can understand the content of every specimen from the start. Visiopharm’s technology enables the development of algorithms that impact each phase of the tissue journey from excision to digitization. The need for rapid and automated quality assessment tools ensures precision pathology is achieved for every cancer patient.
Offered via the ARCH Ecosystem, TriMetis Computer-Assisted Pathology (TCAP) AI quality control applications can identify tumor purity (% tumor and % necrosis), nuclei count, and tumor density heatmap. This development creates new precedence for tumor purity tools that are specifically designed to streamline specimen selection, segmentation, grading, and cellular identification. These applications can be automated, saving time and money while increasing throughput.
Delivered via the web, users can choose to run TCAP applications per click or subscribe for volume discounts. Paired with digital imaging management and laboratory workflow, TriMetis and Visiopharm’s partnership offers scalable platforms for AI creation, validation, and delivery of cutting-edge technologies and automation.
“Our partnership with TriMetis will provide the cancer research community with one of the most important measurements in quality: ensuring that they are using the right tissue material, backed by quantitation. Knowing the tumor area and nuclei count present in each sample is critical for research, biomarker development, genetic testing, and even clinical labs. These new tools could save time and money with increased confidence in the results,” said Christian Kaltoft, Chief Operation Officer of Visiopharm.
“We are excited to work with Visiopharm to jointly provide groundbreaking possibilities in research, pathology, diagnostics, and ultimately patient care. The ARCH Ecosystem and TCAP AI provide the catalyst for a new level of utility by combining innovative computer-assisted pathology AI with an easy-to-use digital image ecosystem, opening opportunities for innovation and automation in pathology and molecular testing services,” said Phil Cestaro, Chief Executive Officer of TriMetis.
At TriMetis Life Sciences, we are revolutionizing the 100-year-old process by doing more faster and with less handling and more accuracy. This creates increased access to quality biospecimens, better decisions, and higher throughput. Access the AI’s via a web-based ARCH Marketplace and automated image handling and workflow management with the ARCH LabFlow Module.
Visiopharm is a world leader in AI-driven precision pathology software. Their pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, the biopharmaceutical industry, and diagnostic centers. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
TriMetis’ partnership with Visiopharm will undoubtedly bring unparalleled access to AI-driven quality applications for medical solution development and research. The possibilities are endless with the combination of innovative computer-assisted pathology AI and an easy-to-use digital image ecosystem. This partnership is truly groundbreaking and will pave the way for innovation and automation in pathology and molecular testing.
